Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-25-243819

Chief Executive Officer sold 50,895 shares at $67.91 ($3,456,279)

  • Chief Executive Officer acquired 100,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kulkarni Samarth · Chief Executive Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-16 Exercise or conversion : show line 1 in the form +100,000 305,096 D
2025-10-17 Sale : show line 2 in the form −50,895 $67.91 $3,456,279 254,201 D
Open-market sales · 50,895 sh · avg $67.91 · $3,456,279

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-10-16 Exercise or conversion : show line 3 in the form Restricted Stock Units −100,000 300,000 D
Loading xslF345X05/ownership.xml…